CareDx (CDNA) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
CareDx Announces CFO Transition
March 24, 2016 4:02 PM EDTBRISBANE, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today announced that Charles Constanti will become its new chief financial officer, replacing Ken Ludlum, who will be leaving CareDx after a transition period. Mr. Constanti will assume the role in early April 2016 and Mr. Ludlum will remain with CareDx through June to ensure a smooth transition.
"During his two years at CareDx, Ken helped us complete our IPO, strengthen the financial organization... More
CareDx, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
March 24, 2016 4:01 PM EDTBRISBANE, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients, today reported financial results for the fourth quarter and full year ended December 31, 2015.Â
Recent Highlights:
For the full year 2015, revenue was $28.1 million versus $27.3 million in 2014, an increase of 3%. Total revenue in 2014 included a $1.1 million one-time payment from LabCorp recorded in the fourth quarter. Revenue from AlloMap®, the Company's flagship molecular diagnostic surveillance solution, grew to... More